NICE To Lose Cost Watch-dog Status By 2013
The National Institute for Health and Clinical Excellence (NICE) will likely no longer have any role in drug cost-effectiveness decisions after 2013, according to UK ministers speaking in London on October 25. Instead, a new value-based pricing system will see drug prices set to reflect a product's worth in the first place, without the need for NICE to carry out its assessment once a drug is already available.News of an end to NICE's most controversial activity will be welcomed by the many companies that have seen their products' commercial potential in the UK severely limited by a negative assessment from the cost watchdog - even though details of the alternative, value-based pricing, are far from clear.
You may also be interested in...
The United Kingdom is creating a £600 million Cancer Drugs Fund to improve treatment access but a consultation document on the initiative is doing little to ease concerns about regional disparities in care.
An independent report into how NICE values medicines concludes that the basis of its cost-effectiveness assessment is sound, but can be improved. And more transparency would help.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.